Laura Bravo-Clemente

Pharmacokinetics of caffeine and its metabolites in plasma and urine after consuming a soluble green/roasted coffee blend by healthy subjects

Coffee is widely consumed worldwide; therefore, the methylxanthines contained in coffee, mainly caffeine (CF), are among the most abundant bioactive compounds in our diet. In the present work, the bioavailability and metabolism of methylxanthines in a commercial soluble green/roasted coffee blend was studied. After a 3-day restriction of methylxanthine-containing foods, fasting healthy subjects (12 men and women) consumed the coffee product containing 70.69mg CF and 0.119mg theobromine (TB). Plasma samples were taken before (t=0h) and after coffee consumption at different time points (0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 9, 10 and 12h). Urine was collected at baseline (-2-0h) and at different intervals (0-2, 2-5, 5-8, 8-12 and 12-24h). Samples were analyzed by HPLC-DAD and LC-MS-QToF, and pharmacokinetic parameters were calculated. CF was the main methylxanthine found in plasma (Cmax=10.50μM, Tmax=1.2h). In addition, seven methylxanthines and methyluric acids were detected between 0.5 and 12h after coffee intake, paraxanthine (PX) being the major metabolite (Cmax=3.36μM), followed by 1-methyluric acid (1-MU; Cmax=1.44μM) and 1-methylxanthine (1-MX; Cmax=1.27μM), identified in plasma samples for the first time. In 24h urine, eleven methylxanthines and methyluric acids were detected, 1-MU being the major metabolite (Cmax=150.52μM, Tmax=12h) amounting to 67.7% of the total urinary metabolites. In conclusion, a rapid absorption, metabolization and excretion of caffeine and its derived methylxanthines and methyluric acids have been observed after consumption of a green/roasted coffee product.

Evaluation of the Bioavailability and Metabolism of Nitroderivatives of Hydroxytyrosol Using Caco-2 and HepG2 Human Cell Models

Considering that nitrocatechols present putative effects against Parkinsons disease, the absorption and metabolism of nitroderivatives of hydroxytyrosol (HT) were assessed using human cell model systems. The test compounds nitrohydroxytyrosol (NO2HT), nitrohydroxytyrosyl acetate (NO2HT-A), and ethyl nitrohydroxytyrosyl ether (NO2HT-E) were efficiently transferred across human Caco-2 cell monolayers as an intestinal barrier model, NO2HT-A and NO2HT-E being better (p < 0.05) absorbed (absorption rate (AR) = 1.4 ± 0.1 and 1.5 ± 0.2, respectively) than their precursor, NO2HT (AR = 1.1 ± 0.1). A significant amount of the absorbed compounds remained unconjugated (81, 70, and 33% for NO2HT, NO2HT-A, and NO2HT-E, respectively) after incubation in Caco-2 cells, being available for hepatic metabolism. Nitrocatechols were extensively taken up and metabolized by human hepatoma HepG2 cells as a model of the human liver. Both studies revealed extensive hydrolysis of NO2HT-A into NO2HT, whereas NO2HT-E was not hydrolyzed. Glucuronide (75-55%), methylglucuronide (25-33%), and methyl derivatives (0-12%) were the main nitrocatechol metabolites detected after metabolism in Caco-2 and HepG2 cells. In conclusion, NO2HT, NO2HT-A, and NO2HT-E show high in vitro bioavailability and are extensively metabolized by hepatic cells.

TNF-α-induced oxidative stress and endothelial dysfunction in EA.hy926 cells is prevented by mate and green coffee extracts, 5-caffeoylquinic acid and its microbial metabolite, dihydrocaffeic acid

Abstract The main phenol in mate and coffee, 5-caffeoylquinic-acid (5-CQA), and its relevant microbial metabolites, dihydrocaffeic (DHCA) and dihydroferulic (DHFA) acids, have shown oxidative-stress protective effects in HepG2 cells. To evaluate possible endothelial-protective effects of the extracts and compounds, endothelial EA.hy926 cells were pre-treated with yerba mate (YME) and green coffee bean (GCBE) phenolic extracts, 5-CQA, DHCA and DHFA and afterwards stressed with tumour-necrosis-factor-alpha (TNF-α). Then oxidative-stress markers and endothelial-nitric-oxide-synthase levels were studied. TNF-α (10 ng/mL, 24 h) depleted reduced glutathione (GSH) and eNOS levels, increased reactive oxygen species (ROS) production, glutathione peroxidase (GPx) and reductase (GR) activities, and protein oxidation (carbonyl groups, CG) in EA.hy926 cells. Pre-treatment with YME, GCBE, 5-CQA, DHCA at certain physiological concentrations, lowered ROS production, recovered depleted GSH, reduced GR and GPx activities, and CG levels, and enhanced eNOS concentration.. YME, GCBE and 5-CQA show antioxidant effects in endothelial cells playing DHCA an important role in such protection; moreover, the extracts, 5-CQA, DHCA and DHFA increased eNOS levels.